Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.

Leukemia research - 1 Jan 2021

Djamai Hanane, Berrou Jeannig, Dupont Mélanie, Kaci Anna, Ehlert Jan Erik, Weber Holger, Baruchel André, Paublant Fabrice, Prudent Renaud, Gardin Claude, Dombret Hervé, Braun Thorsten

Abstract excerpt

Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kinase and Rho GTPase. Upon activation by ROCK, LIM kinases (LIMK) inactivate cofilin by phosphorylation which affects cytoskeleton dynamics, cell growth and apoptosis....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Drug Synergism

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Gene Expression Regulation, Leukemic

Share to Lim Kinases

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Small Molecule Libraries

Source

Identifiers

PMID: 33373830
DOI: 10.1016/j.leukres.2020.106490

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.PMID 33373830Read ↗

Requirement for LIM kinases in acute myeloid leukemia.Semantic proximity Read ↗

Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3-ITD-Mutant Acute Myeloid Leukaemia.Semantic proximity Read ↗

Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.Semantic proximity Read ↗

LIM kinases: cofilin and beyondSemantic proximity Read ↗

A novel approach for relapsed/refractory FLT3mut+ acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib.Semantic proximity Read ↗

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with <i>NRAS</i> mutations to FLT3 inhibitorsSemantic proximity Read ↗

Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Semantic proximity Read ↗

Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells.Semantic proximity Read ↗

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.Semantic proximity Read ↗

Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interactionSemantic proximity Read ↗

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.